Routes of
administration IV CAS Number 110267-81-7 Molar mass 483.46 g/mol | ATC code L01DB10 (WHO) PubChem CID 178149 | |
 | ||
AHFS/Drugs.com International Drug Names Legal status In general: ℞ (Prescription only) | ||
Joachim von pawel germany randomized phase 3 trial of amrubicin versus topotecan
Amrubicin (INN; previously known as SM-5887) is an anthracycline used in the treatment of lung cancer. It is marketed in Japan since 2002 by Sumitomo under the brand name Calsed.
Contents
- Joachim von pawel germany randomized phase 3 trial of amrubicin versus topotecan
- What does amrubicin mean
- References
Amrubicin acts by inhibiting topoisomerase II, and has been compared in clinical trials with topotecan, a Topoisomerase I inhibitor.
It has also been studied for the treatment of bladder carcinoma and gastric cancer.
Amrubicin was the first anthracycline derivative created by de novo synthesis and was first published in 1989 by scientists from Sumitomo.
What does amrubicin mean
References
Amrubicin Wikipedia(Text) CC BY-SA